コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 had 4 or more CRLM, and 22.5% had associated extrahepatic disease.
2 lly appraise key studies on NAFLD-associated extrahepatic disease.
3 evaluation because of accurate assessment of extrahepatic disease.
4 for patients with resectable tumors without extrahepatic disease.
5 tients with liver metastases and concomitant extrahepatic disease.
6 ted for resection of hepatic metastases with extrahepatic disease.
7 ly absolute contraindication to resection is extrahepatic disease.
8 h 4 having intrahepatic disease and 7 having extrahepatic disease.
9 e than 3 liver metastases, R1 resection, and extrahepatic disease.
10 ) for hepatic diseases; 1.35 (1.15-1.57) for extrahepatic diseases; 1.50 (1.10-2.03) for circulatory
12 ighly selected patients with single sites of extrahepatic disease, although expectations should be di
14 correlated with the severity of hepatic and extrahepatic disease and systemic inflammatory responses
15 performance status, macrovascular invasion, extrahepatic disease, and alpha-fetoprotein level to bes
16 or B, ECOG performance status of 0 to 2, no extrahepatic disease, and no prior radiation received 15
17 or and metastases, CRLM number and diameter, extrahepatic disease, and preoperative chemotherapy.
20 onous presentation, primary node status, and extrahepatic disease as matching variables to compare ov
21 rred in all eight of the 17 patients who had extrahepatic disease at pretherapy CT and in four of the
23 iteria required that all patients be free of extrahepatic disease based on computed tomography scans
28 ectal liver metastases (CRLM) and concurrent extrahepatic disease (EHD), and to define prognostic fac
29 ectal liver metastases (CRLM) and concurrent extrahepatic disease (EHD), and to define prognostic fac
30 eater than 200 ng/mL, multiple liver tumors, extrahepatic disease, large tumors, or positive resectio
32 tion contraindications included unresectable extrahepatic disease, more than 70% liver involvement, l
33 s performed at the time of laparotomy unless extrahepatic disease or unresectable hepatic tumors were
34 riate analysis: positive margin (p = 0.004), extrahepatic disease (p = 0.003), node-positive primary
38 These studies concluded that the presence of extrahepatic disease should be a contraindication to res
39 s had higher mortality from both hepatic and extrahepatic diseases, showing multivariate-adjusted haz
40 AFLD may be a new, and added risk factor for extrahepatic diseases such as CVD, chronic kidney diseas
41 al after resection is worse in patients with extrahepatic disease than in patients with liver-only di
42 nificantly higher mortality from hepatic and extrahepatic diseases than anti-HCV seropositives with u
43 erapy [n = 1], lack of regeneration [n = 2], extrahepatic disease undetected prior to PVE [n = 7]).
46 al less than 12 months, multiple tumors, and extrahepatic disease were independent predictors of poor
47 , absence of postoperative chemotherapy, and extrahepatic disease were predictive of recurrence (HR=2
48 h unresectable liver metastases and no known extrahepatic disease were treated concurrently with intr
49 nvasion (HR = 2.2; P = 0.03), but not pre-LT extrahepatic disease, were significant risk factors for
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。